MedPath

50% effective concentration of sevoflurane for immobility in cerebral palsy children undergoing botulinum toxin injectio

Not Applicable
Completed
Conditions
Diseases of the nervous system
Registration Number
KCT0007372
Lead Sponsor
Yeongnam University Medical Center
Brief Summary

ine (42.9%) patients at each target end-tidal concentration of sevoflurane showed purposeful limb movement in response to botulinum toxin injection. Using Dixon’s up-and-down method, the 50% effective concentration (EC50) of sevoflurane for successful botulinum toxin injection in spontaneously breathing children with CP was 1.76 ± 0.15% (95% Confidene interval; CI 1.62–1.90). By probit regression analysis, the predicted EC50 and 95% effective concentration (EC95) of sevoflurane for successful botulinum toxin injection in children with CP were 1.77% (95% CI 1.59–2.35) and 2.09% (95% CI 1.89–5.80), respectively. Changes in hemodynamic and respiratory data, BIS values, and University of Michigan Sedation Scale (UMSS) and Modified Observer’s Assessment of Alertness and Sedation scale (MOAAS) scores throughout the study period in patients with ‘movement’ and ‘no movement’ were comparable. However, the UMSS scores [3.8 ± 0.3 vs. 3.0 ± 0.5, p = 0.001] were higher and MOAAS scores [0.3 ± 0.4 vs. 1.1 ± 0.3, p < 0.001] were lower in patients with ‘movement’ than in those without movement at needle placement.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
21
Inclusion Criteria

? Cerebral horses scheduled to be injected with botulinum toxin after deep sedation
Non-pediatric patients (3-12 years old)
? American Society of Anesthesiologist (ASA) physical grade 1-2
ASA PS 1 (healthy patient without systemic disease)
ASA PS 2 (Patients with mild systemic disease (no substantial dysfunction)

Exclusion Criteria

? Body Mass Index 30 kg/m2 or more
? unstable heart disease
? It is expected that airway management will be difficult
: Difficult airway intubation is expected or experience, congenital facial or airway malformation
? Recent (<2 weeks) history of acute upper respiratory tract disease or asthma
? gastroesophageal reflux disease
? Allergy to general anesthetics and drugs planned for use in this study

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
50% effective concentration of sevoflurane for immobility during botulinum toxin injection in pediatric patients with cerebral palsy
Secondary Outcome Measures
NameTimeMethod
Sedation score measured at a predetermined sevoflurane concentration in a pediatric patient with cerebral palsy.
© Copyright 2025. All Rights Reserved by MedPath